Skip to content
V1777-21 ·8 June 2021 ·consulta-vinculante Medium impact
Tax

Article 23 LIS reduction inapplicable to biosimilar drug licensing if classified as formulas or know-how

A pharmaceutical industry association queried whether income from licensing biosimilar medicines could benefit from the intangible asset reduction. The Directorate General for Taxes (DGT) ruled that this is not possible, as these assets are classified as formulas or information regarding scientific experience.

In 6 key points

How it affects those involved

Companies licensing biosimilar drugs may be unable to access tax relief under Article 23 of the Corporate Income Tax Act if the underlying assets are categorised as scientific formulas or know-how rather than qualifying intangible assets.

Lifecycle

2021-06-08PublishedPublished in the BOE
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The tax team reviews your specific situation.

Talk to the tax team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BM Consulting.
Email
Contact